September 25, 2021
PM mention Gennova’s vaccine at UNGA
PM Modi mentioned Gennova’s vaccine during his address to the UNGA- 25th Sep, 2021
Prime Minister Narendra Modi, today stated that India’s first mRNA vaccine is in final stages. He was referring to the mRNA vaccine being developed by Gennova Biopharma, a subsidiary of Pune based Emcure Pharmaceuticals.
While addressing the UN General Assembly’s 76th session, he said, “India has developed the world’s first DNA vaccine. An m-RNA vaccine is in the final stages of development. Indian scientists are also developing a nasal vaccine against COVID19.”
The Drug Controller General of India, had approved Phase II and Phase III study protocols for HGCO19, India’s first mRNA-based COVID-19 vaccine, developed by Gennova Biopharmaceuticals Limited (“Gennova”) back in August.
Gennova had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India’s National Regulatory Authority (NRA).
The Vaccine Subject Expert Committee (SEC) had reviewed the interim Phase I data, and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study.
The study is being conducted in India at approximately 10-15 sites in Phase II and 22-27 sites in Phase III. Gennova is using the DBT-ICMR clinical trial network sites for this study.
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited (“EPL”) is one of the leading Indian pharmaceutical companies (Source: Report titled “Assessment of the global and Indian pharmaceuticals industry” dated August 2021 prepared by CRISIL Research) headquartered in Pune with global footprint. Driven by strong inhouse research and development with focus on technology and innovation, the company’s mission has been to develop a differentiated portfolio of pharmaceutical products and address unmet patient needs. Established in 1981, the firm was founded by Mr. Satish Mehta and isranked as the 12th largest pharmaceutical company in India (Source: CRISIL). It is the largest pharmaceutical company in India in gynaecology, blood-related and HIV antiviral therapeutic areas based on sales in India in the Financial Year 2021 (Source: CRISIL). Emcure’s subsidiary Gennova is developing India’s first mRNA COVID-19 vaccine for the novel coronavirus using its in-house developed indigenous mRNA platform. To know more about EPL, please visit: https://www.emcure.com/ Follow us on LinkedIn: https://www.linkedin.com/company/emcure-pharmaceuticals-limited/
About Gennova Biopharmaceuticals
Gennova Biopharmaceuticals Limited, the subsidiary of EPL is headquartered in Pune. The company is dedicated to biotherapeutics’ research, development, production, and commercialization to address life-threatening diseases across various indications. It has commercialized 6 biologics in India and Emerging Markets. Gennova has over years collaborated with global academia and leading institutions, including the USFDA and Bill & Melinda Gates Foundation. It is in a unique position to provide an end-to-end solution for vaccine development rapidly. The group has made a novel mRNA based vaccine candidate HGCO19, using spike protein of the virus, reported to interact with receptor on host cells, along with nano-lipid carrier as mRNA vaccine delivery system. To know more, visit https://gennova.bio
“Emcure Pharmaceuticals Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offering of its equity shares and has filed a draft red herring prospectus dated 18 August 2021 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the websites of SEBI, Axis Capital Limited, BofA Securities India Limited, Credit Suisse Securities (India) Private Limited, JM Financial Limited and BOB Capital Markets Limited at www.sebi.gov.in, www.axiscapital.co.in, www.ml-india.com, www.creditsuisse.com, www.jmfl.com and www.bobcaps.in respectively. Investors should note that investment in equity shares involves a high degree of risk and for details refer to the Red Herring Prospectus, including the section titled “Risk Factors” of the Red Herring Prospectus when available. Potential investors should not rely on the DRHP for any investment decision.”
To know more about Emcure, please visit:
Follow us on LinkedIn:
Media Contact Information:
Aasiya Shaikh: 9833503994 (Adfactors PR)
Syed Talal: 9987619679 (Adfactors PR)
Naveen Soni: firstname.lastname@example.org (Corporate Communications)